

Aitziber Buqu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6079886/aitziber-buque-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55
papers

4,616
citations

23
h-index

61
g-index

61
ext. papers

6,122
ext. citations

10.8
avg, IF

5.89
L-index

#	Paper	IF	Citations
55	Cytofluorometric assessment of cell cycle progression in irradiated cells. <i>Methods in Cell Biology</i> , 2022 ,	1.8	1
54	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.. <i>Nature Reviews Drug Discovery</i> , 2022 ,	64.1	7
53	Cytofluorometric assessment of acute cell death responses driven by radiation therapy. <i>Methods in Cell Biology</i> , 2022 ,	1.8	
52	RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells. <i>Methods in Cell Biology</i> , 2022 ,	1.8	
51	Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells. <i>STAR Protocols</i> , 2021 , 2, 100488	1.4	2
50	Possible mechanisms of cancer prevention by nicotinamide. <i>British Journal of Pharmacology</i> , 2021 , 178, 2034-2040	8.6	3
49	Immunomodulation by targeted anticancer agents. <i>Cancer Cell</i> , 2021 , 39, 310-345	24.3	44
48	MPA/DMBA-driven mammary carcinomas. <i>Methods in Cell Biology</i> , 2021 , 163, 1-19	1.8	0
47	LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. <i>OncImmunology</i> , 2021 , 10, 1962592	7.2	12
46	Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1855-1863	12.9	17
45	Ketosis versus carbotoxicity - metabolism determines the outcome of cancer immunotherapy. <i>Molecular and Cellular Oncology</i> , 2021 , 8, 1868266	1.2	1
44	Targeting Serine in Cancer: Is Two Better Than One?. <i>Trends in Cancer</i> , 2021 , 7, 668-670	12.5	1
43	PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. <i>OncImmunology</i> , 2020 , 9, 1721810	7.2	31
42	Methods to Detect Immunogenic Cell Death In Vivo. <i>Methods in Molecular Biology</i> , 2020 , 2055, 433-452	1.4	4
41	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 725-741	19.4	223
40	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020 , 11, 3819	17.4	41
39	Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. <i>Nature Immunology</i> , 2020 , 21, 1160-1171	19.1	94

38	Monitoring abscopal responses to radiation in mice. <i>Methods in Enzymology</i> , 2020 , 635, 111-125	1.7	2
37	Apoptotic caspases cut down the immunogenicity of radiation. <i>Oncolimmunology</i> , 2019 , 8, e1655364	7.2	14
36	Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. <i>Oncolimmunology</i> , 2019 , 8, e1655964	7.2	55
35	Today's Special on the Anticancer Menu: Immunomodulation by Antifolates. <i>Clinical Cancer Research</i> , 2019 , 25, 6890-6892	12.9	
34	Anticancer effects of anti-CD47 immunotherapy. <i>Oncolimmunology</i> , 2019 , 8, 1550619	7.2	19
33	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolimmunology</i> , 2018 , 7, e1433982	7.2	23
32	Modeling Tumor Immunology and Immunotherapy in Mice. <i>Trends in Cancer</i> , 2018 , 4, 599-601	12.5	46
31	Reply: Immunosuppressive cell death in cancer. <i>Nature Reviews Immunology</i> , 2017 , 17, 402	36.5	8
30	Reply: The complement system is also important in immunogenic cell death. <i>Nature Reviews Immunology</i> , 2017 , 17, 143	36.5	5
29	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017 , 280, 165-174	11.3	52
28	Immunogenic cell death in cancer and infectious disease. <i>Nature Reviews Immunology</i> , 2017 , 17, 97-111	36.5	1257
27	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. <i>Oncolimmunology</i> , 2016 , 5, e1088631	7.2	81
26	The ratio of CD8/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma. <i>Oncolimmunology</i> , 2016 , 5, e1218106	7.2	39
25	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolimmunology</i> , 2016 , 5, e1214790	7.2	51
24	Prevention of breast cancer by RANKL/RANK blockade. <i>Cell Research</i> , 2016 , 26, 751-2	24.7	2
23	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. <i>Oncolimmunology</i> , 2016 , 5, e1139275	7.2	17
22	Trial Watch-Immunostimulation with cytokines in cancer therapy. <i>Oncolimmunology</i> , 2016 , 5, e1115942	7.2	35
21	Trial Watch-Oncolytic viruses and cancer therapy. <i>Oncolimmunology</i> , 2016 , 5, e1117740	7.2	76

20	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Onc Immunology</i> , 2016 , 5, e1149674	7.2	41
19	Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer. <i>Journal of Cancer Therapy</i> , 2016 , 07, 455-463	0.2	
18	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016 , 30, 147-160	24.3	285
17	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Onc Immunology</i> , 2015 , 4, e1008814	7.2	68
16	eIF2 β phosphorylation as a biomarker of immunogenic cell death. <i>Seminars in Cancer Biology</i> , 2015 , 33, 86-92	12.7	73
15	Trial Watch: Adoptive cell transfer for oncological indications. <i>Onc Immunology</i> , 2015 , 4, e1046673	7.2	22
14	Podocalyxin-like protein 1 functions as an immunomodulatory molecule in breast cancer cells. <i>Cancer Letters</i> , 2015 , 368, 26-35	9.9	10
13	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Onc Immunology</i> , 2015 , 4, e1026531	7.2	22
12	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. <i>Cancer Cell</i> , 2015 , 28, 690-714	24.3	828
11	Trial Watch: Peptide-based anticancer vaccines. <i>Onc Immunology</i> , 2015 , 4, e974411	7.2	81
10	Morphometric analysis of immunoselection against hyperploid cancer cells. <i>Oncotarget</i> , 2015 , 6, 41204-153	15.3	13
9	Final results of a phase II study of bevacizumab, cisplatin and pemetrexed as first-line therapy for patients with advanced non squamous non small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e19036-e19036	2.2	
8	Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. <i>Clinical and Translational Oncology</i> , 2014 , 16, 339-50	3.6	21
7	Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer. <i>PLoS ONE</i> , 2014 , 9, e109659	3.7	18
6	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
5	Consensus guidelines for the detection of immunogenic cell death. <i>Onc Immunology</i> , 2014 , 3, e955691	7.2	524
4	Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells. <i>PLoS ONE</i> , 2013 , 8, e63338	3.7	18
3	Elderly patients and ovarian epithelial cancer (OEC) or primary peritoneal carcinoma (PPC): A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20718-e20718	2.2	

- 2 Preoperative chemoradiotherapy (QT-RT) with capecitabine and oxaliplatin (CAPOX) or capecitabine alone (CAP) in patients (PTS) with locally advanced rectal cancer (LARC).. *Journal of Clinical Oncology*, **2013**, 31, e14712-e14712 2.2
- 1 Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells. *Molecular Cancer*, **2012**, 11, 25 42.1 24